Nordhealth AS (OSL:NORDH) ROCE %: -31.50% (As of Mar. 2026)

What is Nordhealth AS ROCE %?

Nordhealth AS OSL:NORDH -2.40% 75 ROCE % is -31.50% as of Mar. 2026. GuruFocus rates OSL:NORDH with a GF Score™ of 75/100 and a GF Value™ of kr38.89 (Significantly Undervalued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nordhealth AS's annualized ROCE % for the quarter that ended in Mar. 2026 was -31.50%.

Nordhealth AS (OSL:NORDH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Nordhealth AS ROCE % Related Terms

Nordhealth AS ROCE % Historical Data

* Premium members only.

The historical data trend for Nordhealth AS's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nordhealth AS ROCE % Chart

Nordhealth AS Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-7.39

-13.40

-12.49

-8.51

-18.16

Nordhealth AS Quarterly Data
	Apr21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-14.51	-17.07	-12.95	-27.97	-31.50

75GF Score

Nordhealth AS OSL:NORDH

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Nordhealth AS ROCE % Calculation

Nordhealth AS's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-144.952	/	( ( (974.753 - 106.893)	+	(846.518 - 117.91) )	/ 2 )
	=	-144.952	/	( (867.86	+	728.608)	/ 2 )
	=	-144.952	/	798.234
	=	-18.16 %

Nordhealth AS's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-217.56	/	( ( (846.518 - 117.91)	+	(814.829 - 161.985) )	/ 2 )
	=	-217.56	/	( ( 728.608	+	652.844 )	/ 2 )
	=	-217.56	/	690.726
	=	-31.50 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -31.50% mean?

Nordhealth AS (OSL:NORDH) has a ROCE % of -31.50% as of Mar. 2026.

Is Nordhealth AS's ROCE % too high?

Nordhealth AS's current ROCE % is -31.50%. Overall, Nordhealth AS has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Nordhealth AS's ROCE % compare to VEEV and BTSG?

Nordhealth AS's ROCE % of -31.50% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Healthcare Providers & Services company?

The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 646 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nordhealth AS's current ROCE % is -31.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Nordhealth AS stock overvalued right now?

Based on GuruFocus' analysis, Nordhealth AS (OSL:NORDH) is currently considered Significantly Undervalued. The stock's GF Value™ is kr38.89, compared to a current price of kr24.40 — trading 37.3% below its estimated fair value. The current ROCE % is -31.50%. Nordhealth AS's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Nordhealth AS (OSL:NORDH), the current ROCE % is -31.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nordhealth AS (OSL:NORDH) Overvalued in 2026?

Based on GuruFocus' analysis, Nordhealth AS stock appears to be undervalued. The current stock price of kr24.40 is trading 37.3% below its estimated GF Value™ of kr38.89. GuruFocus considers Nordhealth AS to be Significantly Undervalued.

Key valuation signals for OSL:NORDH:

ROCE %: -31.50%
GF Value™: kr38.89 vs. price of kr24.40 (37.3% below fair value)
GF Score™: 75/100 with 1 warning sign

No single metric tells the full story. See the OSL:NORDH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nordhealth AS Business Description

Industry Healthcare Healthcare Providers & Services

Comparable Companies OSL:OMDA OSL:CONTX OSL:CODE OSL:INDCT VEEV ASX:PME BTSG TEM HQY TSE:2413 HNGE TXG DOCS WAY HKSE:02228 PRVA HTFL NSE:IKS SZSE:300253 NSE:SAGILITY

Address Hasleveien 28A, Oslo, NOR, 0571

Website https://www.nordhealth.com

Nordhealth AS is a cloud-based healthcare Software-as-a-Service business. Its flagship Practice Management Software (PMS), Provet for veterinary practices and Therapy Unified Platform for therapy practices, assist healthcare professionals to streamline operations and improve patient care. The majority of its revenue is generated through software subscriptions. The Group also offers additional services related to the implementation of the SaaS systems, including consultancy services, education, and data conversion. Its operating segments are: Veterinary, which generates the majority of revenue, Therapy, and Other. Geographically, Nordhealth derives maximum revenue from Norway, and the rest from Finland, the United Kingdom, Sweden, Denmark, the DACH region, and other countries.

75GF Score

Get the complete analysis for OSL:NORDH

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr24.40

Price

kr38.89

GF Value

View OSL:NORDH Analysis

See ROCE % data for all stocks →